Suppr超能文献

针对严重急性呼吸综合征冠状病毒单个蛋白的抗体反应及其中和活性。

Antibody responses to individual proteins of SARS coronavirus and their neutralization activities.

作者信息

Qiu Maofeng, Shi Yuling, Guo Zhaobiao, Chen Zeliang, He Rongqiao, Chen Runsheng, Zhou Dongsheng, Dai Erhei, Wang Xiaoyi, Si Bingyin, Song Yajun, Li Jingxiang, Yang Ling, Wang Jin, Wang Hongxia, Pang Xin, Zhai Junhui, Du Zongmin, Liu Ying, Zhang Yong, Li Linhai, Wang Jian, Sun Bing, Yang Ruifu

机构信息

Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, No. 20, Dongdajie, Fengtai District, Beijing 100071, China.

出版信息

Microbes Infect. 2005 May;7(5-6):882-9. doi: 10.1016/j.micinf.2005.02.006. Epub 2005 Apr 13.

Abstract

A novel coronavirus, the severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV), was identified as the causative agent of SARS. The profile of specific antibodies to individual proteins of the virus is critical to the development of vaccine and diagnostic tools. In this study, 13 recombinant proteins associated with four structural proteins (S, E, M and N) and five putative uncharacterized proteins (3a, 3b, 6, 7a and 9b) of the SARS-CoV were prepared and used for screening and monitoring their specific IgG antibodies in SARS patient sera by protein microarray. Antibodies to proteins S, 3a, N and 9b were detected in the sera from convalescent-phase SARS patients, whereas those to proteins E, M, 3b, 6 and 7a were undetected. In the detectable specific antibodies, anti-S and anti-N were dominant and could persist in the sera of SARS patients until week 30. Among the rabbit antisera to recombinant proteins S3, N, 3a and 9b, only anti-S3 serum showed significant neutralizing activity to the SARS-CoV infection in Vero E6 cells. The results suggest (1) that anti-S and anti-N antibodies are diagnostic markers and in particular that S3 is immunogenic and therefore is a good candidate as a subunit vaccine antigen; and (2) that, from a virus structure viewpoint, the presence in some human sera of antibodies reacting with two recombinant polypeptides, 3a and 9b, supports the hypothesis that they are synthesized during the virus cycle.

摘要

一种新型冠状病毒,即严重急性呼吸综合征(SARS)冠状病毒(SARS-CoV),被确定为SARS的病原体。针对该病毒个别蛋白质的特异性抗体谱对于疫苗和诊断工具的开发至关重要。在本研究中,制备了与SARS-CoV的四种结构蛋白(S、E、M和N)以及五种假定的未表征蛋白(3a、3b、6、7a和9b)相关的13种重组蛋白,并通过蛋白质微阵列用于筛选和监测SARS患者血清中的特异性IgG抗体。在康复期SARS患者的血清中检测到了针对蛋白S、3a、N和9b的抗体,而未检测到针对蛋白E、M、3b、6和7a的抗体。在可检测到的特异性抗体中,抗S和抗N抗体占主导地位,并且可以在SARS患者血清中持续存在至第30周。在针对重组蛋白S3、N、3a和9b的兔抗血清中,只有抗S3血清对Vero E6细胞中的SARS-CoV感染表现出显著的中和活性。结果表明:(1)抗S和抗N抗体是诊断标志物,特别是S3具有免疫原性,因此是作为亚单位疫苗抗原的良好候选者;(2)从病毒结构的角度来看,一些人血清中存在与两种重组多肽3a和9b反应的抗体,支持了它们在病毒周期中合成的假说。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9173/7110836/37c07cd09605/gr1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验